Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?

Sarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip, Tom John, Ian Kerridge

Open source

DOI
10.1177/17407745261469887
Published
2026-09-11
Container
Clinical Trials
Publisher
SAGE Publications
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/17407745261469887,
  title = {Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?},
  author = {Sarah Heynemann and Wendy Lipworth and Sue-Anne McLachlan and Jennifer Philip and Tom John and Ian Kerridge},
  year = {2026},
  journal = {Clinical Trials},
  doi = {10.1177/17407745261469887},
  url = {https://doi.org/10.1177/17407745261469887}
}

RIS

TY  - JOUR
TI  - Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?
AU  - Sarah Heynemann
AU  - Wendy Lipworth
AU  - Sue-Anne McLachlan
AU  - Jennifer Philip
AU  - Tom John
AU  - Ian Kerridge
PY  - 2026
JO  - Clinical Trials
DO  - 10.1177/17407745261469887
UR  - https://doi.org/10.1177/17407745261469887
ER  - 

APA

Heynemann, S., Lipworth, W., McLachlan, S., Philip, J., John, T., & Kerridge, I. (2026). Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?. Clinical Trials. https://doi.org/10.1177/17407745261469887

Source records